ArticleAnnals of neurology2023

Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis.

Zoé L E van Kempen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.